Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Influenza Immune Plasma for Severe Influenza A
NCT02572817Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2015
- Primary completion
- Apr 2018
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anti-influenza immune plasma in Influenza A virus infection (IAV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Clinical Status at Day 7. Started Nov 2015; status: completed.
02
Drugs
anti-influenza immune plasma
03
Conditions
Influenza A virus infection (IAV)
Beyond the preview
Go deeper on NCT02572817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572817.